PT Kimia Farma Tbk (ISX:KAEF) Cyclically Adjusted Revenue per Share: Rp1,874.56 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:KAEF PT Kimia Farma Tbk ISX:KAEF
58 GF Score
Price Rp452.00
GF Value Rp581.11
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is PT Kimia Farma Tbk Cyclically Adjusted Revenue per Share?

PT Kimia Farma Tbk ISX:KAEF -0.88% 58 Cyclically Adjusted Revenue per Share is Rp1,874.56 as of Mar. 2026. GuruFocus rates ISX:KAEF with a GF Score™ of 58/100 and a GF Value™ of Rp581.11 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PT Kimia Farma Tbk's adjusted revenue per share for the three months ended in Mar. 2026 was Rp364.792. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is Rp1,874.56 for the trailing ten years ended in Mar. 2026.

During the past 12 months, PT Kimia Farma Tbk's average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of PT Kimia Farma Tbk was 9.90% per year. The lowest was 6.10% per year. And the median was 7.60% per year.

As of today (2026-07-26), PT Kimia Farma Tbk's current stock price is Rp452.00. PT Kimia Farma Tbk's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was Rp1,874.56. PT Kimia Farma Tbk's Cyclically Adjusted PS Ratio of today is 0.24.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PT Kimia Farma Tbk was 4.54. The lowest was 0.22. And the median was 0.58.


PT Kimia Farma Tbk  (ISX:KAEF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PT Kimia Farma Tbk's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=452.00/1874.56
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PT Kimia Farma Tbk was 4.54. The lowest was 0.22. And the median was 0.58.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PT Kimia Farma Tbk Cyclically Adjusted Revenue per Share Related Terms


PT Kimia Farma Tbk Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for PT Kimia Farma Tbk's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Kimia Farma Tbk Cyclically Adjusted Revenue per Share Chart

PT Kimia Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,403.21 1,547.81 1,653.95 1,746.98 1,848.01

PT Kimia Farma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,768.29 1,798.85 1,821.50 1,848.01 1,874.56

ISX:KAEF vs MCK, CAH, COR: Cyclically Adjusted Revenue per Share Comparison

For the Medical Distribution subindustry, PT Kimia Farma Tbk's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Kimia Farma Tbk Cyclically Adjusted PS Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Tbk's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PT Kimia Farma Tbk's Cyclically Adjusted PS Ratio falls into.


ISX:KAEF
58GF Score
PT Kimia Farma Tbk ISX:KAEF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Kimia Farma Tbk Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PT Kimia Farma Tbk's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=364.792/136.5387*136.5387
=364.792

Current CPI (Mar. 2026) = 136.5387.

PT Kimia Farma Tbk Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 243.292 103.212 321.849
201609 266.086 104.142 348.859
201612 331.970 105.222 430.773
201703 215.694 106.476 276.594
201706 258.838 107.722 328.081
201709 300.040 108.020 379.253
201712 328.683 109.017 411.660
201803 268.309 110.097 332.750
201806 417.569 111.085 513.251
201809 394.442 111.135 484.607
201812 442.771 112.430 537.716
201903 326.761 112.829 395.428
201906 487.935 114.730 580.684
201909 423.854 114.905 503.657
201912 454.021 115.486 536.788
202003 432.531 116.252 508.009
202006 411.510 116.630 481.755
202009 424.538 116.397 498.003
202012 533.036 117.318 620.365
202103 414.151 117.840 479.869
202106 586.554 118.184 677.650
202109 659.993 118.262 761.993
202112 605.696 119.516 691.965
202203 407.005 120.948 459.469
202206 389.693 123.322 431.456
202209 487.677 125.298 531.426
202212 375.917 126.098 407.043
202303 414.777 126.953 446.097
202306 475.114 127.663 508.146
202309 495.190 128.151 527.599
202312 388.290 129.395 409.728
202403 455.880 130.607 476.584
202406 481.075 130.792 502.214
202409 476.157 130.361 498.722
202412 372.705 131.432 387.188
202503 389.504 131.948 403.054
202506 395.420 133.241 405.208
202509 474.054 133.819 483.689
202512 397.931 135.271 401.660
202603 364.792 136.539 364.792

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of Rp1,874.56 mean?
PT Kimia Farma Tbk (ISX:KAEF) has a Cyclically Adjusted Revenue per Share of Rp1,874.56 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PT Kimia Farma Tbk and its competitors.
Is PT Kimia Farma Tbk's Cyclically Adjusted Revenue per Share too high?
PT Kimia Farma Tbk's current Cyclically Adjusted Revenue per Share is Rp1,874.56. Overall, PT Kimia Farma Tbk has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Tbk's Cyclically Adjusted Revenue per Share compare to MCK and CAH?
PT Kimia Farma Tbk's Cyclically Adjusted Revenue per Share of Rp1,874.56 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Distribution company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Distribution industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PT Kimia Farma Tbk and its competitors. PT Kimia Farma Tbk's current Cyclically Adjusted Revenue per Share is Rp1,874.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp581.11, compared to a current price of Rp452.00 — trading 22.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is Rp1,874.56. PT Kimia Farma Tbk's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For PT Kimia Farma Tbk (ISX:KAEF), the current Cyclically Adjusted Revenue per Share is Rp1,874.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Kimia Farma Tbk (ISX:KAEF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Kimia Farma Tbk stock appears to be undervalued. The current stock price of Rp452.00 is trading 22.2% below its estimated GF Value™ of Rp581.11. GuruFocus considers PT Kimia Farma Tbk to be Modestly Undervalued.

Key valuation signals for ISX:KAEF:

  • Cyclically Adjusted Revenue per Share: Rp1,874.56
  • GF Value™: Rp581.11 vs. price of Rp452.00 (22.2% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Kimia Farma Tbk Business Description

Address Jalan Veteran No. 9 Gambir, Jakarta Pusat, Jakarta, IDN, 10110
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
58GF Score

Get the complete analysis for ISX:KAEF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp452.00
Price
Rp581.11
GF Value